New Drugs Research

New Drugs Research

- DETAIL -

Ever Supreme Bio Technology has the capability to self-development, and had received a number of technology transfers from Academia Sinica, National Chiao-Tung University, and China Medical University on cell therapies and technologies, and developed a complete patent portfolio on the new drugs research and development for immune cells and stem cells.

Phase I clinical trial on umbilical cord mesenchymal stem cells (UMC01) for the treatment of acute myocardial infarction (AMI) was permitted by the FDA on February 2018, and approved by the TFDA in September of the same year; new stem cell drugs of Phase I clinical on the indication of stroke by Intravenous (IV) injection also passed by the FDA in September 2018 and by the TFDA in March of 2020.

Also, the dendritic cell vaccine (ADCV01) for the treatment of malignant brain tumors (GBM) has passed the TFDA review, and has been carried out Phase II clinical trials in Chang Gung Memorial Hospital of Linkou, Taichung Veterans General Hospital, and China Medical University Hospital.

In addition, research and development of technologies such as chimeric antigen receptor immune cells (CAR001), magnetic fucoidan nanoparticles, and genetically modified mesenchymal stem cells are continued to progress.